Learn how FDA’s interchangeable ranibizumab biosimilar may streamline injections, cut costs, and guide safe switching for retina patients.
Cyrus Karkaria, PhD
Advertisement
Dr. Cyrus Karkaria is President of Lupin's Biotechnology Businesses, leading the company's global biosimilars portfolio with over 30 years of biologic drug development experience at organizations including Biogen, CuraGen, and Celldex Therapeutics. He holds a post-doctorate from Harvard Medical School and a PhD. from the University of Maryland.
Articles by Cyrus Karkaria, PhD
FDA approves ranibizumab-hkdz as first interchangeable biosimilar ranibizumab available in both vials and prefilled syringes
Published: | Updated:
The FDA has approved ranibizumab-hkdz (Ranluspec; Lupin Limited) as an interchangeable biosimilar for wet AMD, DME, DR, RVO, and mCNV.
Advertisement
Latest Updated Articles
FDA approves ranibizumab-hkdz as first interchangeable biosimilar ranibizumab available in both vials and prefilled syringesPublished: June 5th 2026 | Updated: June 11th 2026
- FDA approves ranibizumab-hkdz as first interchangeable biosimilar ranibizumab available in both vials and prefilled syringes
Published: June 5th 2026 | Updated: June 11th 2026
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Port Delivery System Therapies in Retinal Vascular Diseases
2
Polyendocrine metabolic ovarian syndrome: looking past the reproductive system to the eye
3
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
4
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
5